Lisa V. Hampson

2.5k total citations · 1 hit paper
43 papers, 1.0k citations indexed

About

Lisa V. Hampson is a scholar working on Statistics and Probability, Economics and Econometrics and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Lisa V. Hampson has authored 43 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Statistics and Probability, 22 papers in Economics and Econometrics and 8 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Lisa V. Hampson's work include Statistical Methods in Clinical Trials (30 papers), Health Systems, Economic Evaluations, Quality of Life (22 papers) and Advanced Causal Inference Techniques (10 papers). Lisa V. Hampson is often cited by papers focused on Statistical Methods in Clinical Trials (30 papers), Health Systems, Economic Evaluations, Quality of Life (22 papers) and Advanced Causal Inference Techniques (10 papers). Lisa V. Hampson collaborates with scholars based in United Kingdom, Switzerland and United States. Lisa V. Hampson's co-authors include Thomas Jaki, Christopher Jennison, Graham Wheeler, Christina Yap, Adrian Mander, Philip Pallmann, Munyaradzi Dimairo, Sofía S. Villar, Matthew R. Sydes and Laura Flight and has published in prestigious journals such as Blood, PLoS ONE and British Journal of Cancer.

In The Last Decade

Lisa V. Hampson

41 papers receiving 1.0k citations

Hit Papers

Adaptive designs in clinical trials: why use them, and ho... 2018 2026 2020 2023 2018 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adaptive designs in clinical trials: why use them, and how to run and report them
    2018 415 citations Philip Pallmann, Alun Bedding et al. BMC Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lisa V. Hampson United Kingdom 13 469 298 139 119 114 43 1.0k
Satrajit Roychoudhury United States 15 772 1.6× 283 0.9× 183 1.3× 110 0.9× 96 0.8× 38 1.1k
Babak Choodari‐Oskooei United Kingdom 13 360 0.8× 216 0.7× 96 0.7× 118 1.0× 55 0.5× 32 849
Graham Wheeler United Kingdom 10 278 0.6× 164 0.6× 109 0.8× 80 0.7× 80 0.7× 31 847
Didier Renard Belgium 21 633 1.3× 336 1.1× 98 0.7× 95 0.8× 73 0.6× 42 1.7k
Ariel Alonso Belgium 18 676 1.4× 313 1.1× 130 0.9× 79 0.7× 67 0.6× 85 1.1k
Jonathan Denne United States 15 401 0.9× 91 0.3× 149 1.1× 57 0.5× 105 0.9× 30 1.3k
Spencer Phillips Hey United States 21 282 0.6× 479 1.6× 23 0.2× 99 0.8× 106 0.9× 68 1.5k
Lang’o Odondi United Kingdom 9 199 0.4× 131 0.4× 59 0.4× 69 0.6× 40 0.4× 11 573
Sue‐Jane Wang United States 24 1.4k 3.0× 470 1.6× 727 5.2× 297 2.5× 270 2.4× 73 1.9k
Sam Wieand United States 15 655 1.4× 218 0.7× 95 0.7× 156 1.3× 66 0.6× 24 2.2k

Countries citing papers authored by Lisa V. Hampson

Since Specialization
Citations

This map shows the geographic impact of Lisa V. Hampson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa V. Hampson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa V. Hampson more than expected).

Fields of papers citing papers by Lisa V. Hampson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa V. Hampson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa V. Hampson. The network helps show where Lisa V. Hampson may publish in the future.

Co-authorship network of co-authors of Lisa V. Hampson

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa V. Hampson. A scholar is included among the top collaborators of Lisa V. Hampson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa V. Hampson. Lisa V. Hampson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Asikanius, Elina, Benjamin Hofner, Lisa V. Hampson, et al.. (2025). Clinical trials with interim analyses: standardizing terminology to increase clarity. Trials. 26(1). 247–247.
2.
Oakley, Jeremy E., et al.. (2024). Assurance methods for designing a clinical trial with a delayed treatment effect. Statistics in Medicine. 43(19). 3595–3612. 1 indexed citations
3.
Hao, Yanni, Wei‐Chun Hsu, Craig S. Parzynski, et al.. (2023). Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma. Journal of Comparative Effectiveness Research. 12(7). e220173–e220173. 3 indexed citations
4.
Holzhauer, Björn, Lisa V. Hampson, John Paul Gosling, et al.. (2022). Eliciting judgements about dependent quantities of interest: The SHeffield ELicitation Framework extension and copula methods illustrated using an asthma case study. Pharmaceutical Statistics. 21(5). 1005–1021. 5 indexed citations
5.
Arnold, Philip, Lisa V. Hampson, Annette Davis, et al.. (2021). Study to evaluate the optimal dose of remifentanil required to ensure apnea during magnetic resonance imaging of the heart under general anesthesia. Pediatric Anesthesia. 31(5). 548–556. 1 indexed citations
6.
Hampson, Lisa V., Björn Bornkamp, Björn Holzhauer, et al.. (2021). Improving the assessment of the probability of success in late stage drug development. Pharmaceutical Statistics. 21(2). 439–459. 12 indexed citations
7.
Pallmann, Philip, Fang Wan, Adrian Mander, et al.. (2019). Designing and evaluating dose-escalation studies made easy: The MoDEsT web app. Clinical Trials. 17(2). 147–156. 7 indexed citations
8.
Hampson, Lisa V., et al.. (2019). Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study. BMC Medical Research Methodology. 19(1). 85–85. 9 indexed citations
9.
Gamalo, Margaret, et al.. (2019). Incorporating Innovative Techniques Toward Extrapolation and Efficient Pediatric Drug Development. Therapeutic Innovation & Regulatory Science. 53(5). 567–578. 11 indexed citations
10.
Pallmann, Philip, Alun Bedding, Babak Choodari‐Oskooei, et al.. (2018). Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Medicine. 16(1). 29–29. 415 indexed citations breakdown →
11.
Cook, Natalie, Bristi Basu, D. M. Smith, et al.. (2018). A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer. 118(6). 793–801. 96 indexed citations
12.
Cook, Jonathan, Steven A. Julious, William Sones, et al.. (2017). Choosing the target difference (‘effect size’) for a randomised controlled trial - DELTA2 guidance protocol. Trials. 18(1). 271–271. 7 indexed citations
13.
Hampson, Lisa V., Paula Williamson, Martin Wilby, & Thomas Jaki. (2017). A framework for prospectively defining progression rules for internal pilot studies monitoring recruitment. Statistical Methods in Medical Research. 27(12). 3612–3627. 6 indexed citations
14.
15.
Jaki, Thomas, Graeme J. Sills, Richard Appleton, et al.. (2016). Clinical Drug Development in Epilepsy Revisited: A Proposal for a New Paradigm Streamlined Using Extrapolation. CNS Drugs. 30(11). 1011–1017. 13 indexed citations
16.
Jaki, Thomas & Lisa V. Hampson. (2015). Designing multi‐arm multi‐stage clinical trials using a risk–benefit criterion for treatment selection. Statistics in Medicine. 35(4). 522–533. 7 indexed citations
17.
Hampson, Lisa V., Paula Williamson, Martin Wilby, & Thomas Jaki. (2015). Recruitment progression rules for internal pilot studies monitoring recruitment. Trials. 16(S2).
18.
Hampson, Lisa V., John Whitehead, Despina Eleftheriou, & Paul Brogan. (2014). Bayesian methods for the design and interpretation of clinical trials in very rare diseases. Statistics in Medicine. 33(24). 4186–4201. 69 indexed citations
19.
20.
Whitehead, John, et al.. (2007). A Bayesian Approach for Dose-Escalation in a Phase I Clinical Trial Incorporating Pharmacodynamic Endpoints. Journal of Biopharmaceutical Statistics. 17(6). 1117–1129. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Satrajit Roychoudhury Breakdown of academic impact, for papers by Babak Choodari‐Oskooei Breakdown of academic impact, for papers by Graham Wheeler Breakdown of academic impact, for papers by Didier Renard Breakdown of academic impact, for papers by Ariel Alonso Breakdown of academic impact, for papers by Jonathan Denne Breakdown of academic impact, for papers by Spencer Phillips Hey Breakdown of academic impact, for papers by Lang’o Odondi Breakdown of academic impact, for papers by Sue‐Jane Wang Breakdown of academic impact, for papers by Sam Wieand
Rankless by CCL
2026